Beijing Xinyun Medical Technology Co., Ltd. has officially declared the successful closure of its Series B+ funding round. This particular financing phase was primarily steered by Daotong Investment, with additional support from entities like Taizhou Angel Fund and Qianfeng Investment. Since its inception in 2016, Xinyun Medical has dedicated its efforts to the realm of chronic pain management. The company has propelled product innovation forward by adopting a holistic 'industry-academia-research-medical application' approach, thereby successfully dismantling several foreign technology monopolies. Zhao Yun, the founder of the company, emphasized that this integrated model constitutes the company's primary competitive edge. Moreover, Xinyun Medical has already engaged in collaborative research endeavors with numerous institutions. Representatives from both Daotong Investment and Taizhou Angel Investment Fund expressed their positive outlook on Xinyun Medical's growth trajectory, asserting that it has the potential to introduce groundbreaking solutions to the industry and ultimately enhance the well-being of a broader patient base.